Open access
Open access
Powered by Google Translator Translator

Randomized trial: Benralizumab effects on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma

22 Jan, 2021 | 07:59h | UTC

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.